米国の整形外科用生体材料市場：規模、シェア、動向分析（2024年～2030年）：MedSuite

米国の整形外科用生体材料の市場規模は、2023年に50億米ドル超となっています。この市場はCAGR5.3％で成長し、予測期間中に72億米ドルを超えると予測されています。

整形外科用生体材料市場は、人口動態、特に高齢化と脊椎の変形性関節症（OA）の増加の影響を大きく受けています。脊椎固定術の増加は、OA症例の増加と密接に関連しており、これは高齢化と相関しています。2008年にベビーブーム世代の第一波が定年退職を始めて以来、退行性疾患のリスクを抱える人口が拡大し、骨移植などの治療に対する需要が増加しています。

高齢者人口が増え続け、肥満率が高いままであるため、変性疾患の有病率は上昇すると予想されます。この人口動態の変化は、整形外科用生体材料と修復処置に対するニーズの高まりを強調し、予測期間を通じて市場の成長を促進します。

当レポートでは、米国の整形外科用生体材料市場について調査し、市場の概要とともに、セグメント別動向、COVID-19の影響分析、市場促進要因および阻害要因、競合市場シェア分析、および市場に参入する企業のプロファイルなどを提供しています。

目次

エグゼクティブサマリー

米国の整形外科用生体材料市場概要

• 競合分析
• 市場動向
• 対象手技
• 調査対象の手技コード
• 対象市場
• 主要なレポートの更新
• バージョン履歴
• 調査手法

米国の整形外科用生体材料市場に対するCOVID-19の影響

米国の整形外科用生体材料市場概要

• イントロダクション
  • 骨移植代替品
  • 成長因子
  • 細胞同種移植
  • 細胞療法
  • ヒアルロン酸（HA）関節内補充療法
  • 軟骨修復
• 市場概要と動向分析
• 促進要因と抑制要因
• 競合市場シェア分析
• 合併と買収
• 企業プロファイル
  • Arthrex
  • Biocomposites
  • Bioventus
  • DePuy Synthes
  • Ferring Pharmaceuticals
  • Isto Biologics
  • Medtronic
  • MTF
  • NuVasive
  • Orthofix
  • Sanofi
  • Stryker
  • Terumo
  • Vericel
  • Zimmer Biomet
• SWOT分析
• イントロダクション
• 手技

整形外科用骨移植代替品市場

• イントロダクション
• 市場概要
• 市場分析と予測
• 台数分析
• 促進要因と抑制要因
• 競合市場シェア分析

整形外科用成長因子市場

• イントロダクション
• 市場概要
• 市場分析と予測
• 台数分析
• 促進要因と抑制要因
• 競争市場シェア分析

整形外科用細胞移植市場

• イントロダクション
• 市場概要
• 市場分析と予測
• 促進要因と抑制要因
• 競合市場シェア分析

整形外科用細胞治療市場

• イントロダクション
• 市場概要
• 市場分析と予測
• 台数分析
• 促進要因と抑制要因
• 競合市場シェア分析

ヒアルロン酸関節内補充療法市場

• イントロダクション
• 市場概要
• 市場分析と予測
• 促進要因と抑制要因
• 競合市場シェア分析

整形外科用軟骨修復市場

• イントロダクション
• 市場概要
• 市場分析と予測
• 台数分析
• 促進要因と抑制要因
• 競争市場シェア分析

LIST OF CHARTS

• Chart 1-1: Orthopedic Biomaterials Market by Segment, U.S., 2023 - 2030
• Chart 1-2: Orthopedic Biomaterials Market Overview, U.S., 2023 & 2030
• Chart 2-1: Multi-Scenario Orthopedic Biomaterials Market Forecast, U.S., 2020 - 2030 (US$M)
• Chart 5-1: Orthopedic Biomaterials Market by Segment, U.S., 2020 - 2030
• Chart 5-2: Leading Competitors, Orthopedic Biomaterials Market, U.S., 2023
• Chart 6-1: Orthopedic Biomaterials Procedures by Segment, U.S., 2020 - 2030
• Chart 7-1: Orthopedic Bone Graft Substitute Market by Segment, U.S., 2020 - 2030
• Chart 7-2: Orthopedic Bone Graft Substitute Market by Indication, U.S., 2020 - 2030
• Chart 7-3: Leading Competitors, Orthopedic Bone Graft Substitute Market, U.S., 2023
• Chart 8-1: Orthopedic Growth Factor Market by Segment, U.S., 2020 - 2030
• Chart 8-2: Leading Competitors, Orthopedic Growth Factor Market, U.S., 2023
• Chart 9-1: Orthopedic Cellular Allograft Market by Segment, U.S., 2020 - 2030
• Chart 9-2: Leading Competitors, Orthopedic Cellular Allograft Market, U.S., 2023
• Chart 10-1: Orthopedic Cell Therapy Market by Segment, U.S., 2020 - 2030
• Chart 10-2: Leading Competitors, Orthopedic Cell Therapy Market, U.S., 2023
• Chart 11-1: Hyaluronic Acid (HA) Viscosupplementation Market by Segment, U.S., 2020 - 2030
• Chart 11-2: Leading Competitors, Hyaluronic Acid Viscosupplementation Market, U.S., 2023
• Chart 12-1: Orthopedic Cartilage Repair Market by Segment, U.S., 2020 - 2030
• Chart 12-2: Leading Competitors, Orthopedic Cartilage Repair Market, U.S., 2023

LIST OF FIGURES

• Figure 1-1: Orthopedic Biomaterials Market Share Ranking by Segment, U.S., 2023 (1 of 2)
• Figure 1-2: Orthopedic Biomaterials Market Share Ranking by Segment, U.S., 2023 (2 of 2)
• Figure 1-3: Companies Researched in This Report
• Figure 1-4: Factors Impacting the Orthopedic Biomaterials Market by Segment, U.S. (1 of 2)
• Figure 1-5: Factors Impacting the Orthopedic Biomaterials Market by Segment, U.S. (2 of 2)
• Figure 1-6: Recent Events in the Orthopedic Biomaterials Market, U.S., 2021 - 2024 (1 of 6)
• Figure 1-7: Recent Events in the Orthopedic Biomaterials Market, U.S., 2021 - 2024 (2 of 6)
• Figure 1-8: Recent Events in the Orthopedic Biomaterials Market, U.S., 2021 - 2024 (3 of 6)
• Figure 1-9: Recent Events in the Orthopedic Biomaterials Market, U.S., 2021 - 2024 (4 of 6)
• Figure 1-10: Recent Events in the Orthopedic Biomaterials Market, U.S., 2021 - 2024 (5 of 6)
• Figure 1-11: Recent Events in the Orthopedic Biomaterials Market, U.S., 2021 - 2024 (6 of 6)
• Figure 1-12: Orthopedic Biomaterials Procedures Covered (1 of 4)
• Figure 1-13: Orthopedic Biomaterials Procedures Covered (2 of 4)
• Figure 1-14: Orthopedic Biomaterials Procedures Covered (3 of 4)
• Figure 1-15: Orthopedic Biomaterials Procedures Covered (4 of 4)
• Figure 1-16: Procedure Codes Investigated
• Figure 1-17: Orthopedic Biomaterials Markets Covered (1 of 6)
• Figure 1-18: Orthopedic Biomaterials Markets Covered (2 of 6)
• Figure 1-19: Orthopedic Biomaterials Markets Covered (3 of 6)
• Figure 1-20: Orthopedic Biomaterials Markets Covered (4 of 6)
• Figure 1-21: Orthopedic Biomaterials Markets Covered (5 of 6)
• Figure 1-22: Orthopedic Biomaterials Markets Covered (6 of 6)
• Figure 1-23: Key Report Updates
• Figure 1-24: Version History
• Figure 2-1: Orthopedic Biomaterials Market by Segment, Worst Case Scenario, U.S., 2020 - 2030 (US$M)
• Figure 2-2: Orthopedic Biomaterials Market by Segment, Base Case Scenario, U.S., 2020 - 2030 (US$M)
• Figure 2-3: Orthopedic Biomaterials Market by Segment, Best Case Scenario, U.S., 2020 - 2030 (US$M)
• Figure 4-1: Bone Graft Substitutes Products by Company (1 of 4)
• Figure 4-2: Bone Graft Substitutes Products by Company (2 of 4)
• Figure 4-3: Bone Graft Substitutes Products by Company (3 of 4)
• Figure 4-4: Bone Graft Substitutes Products by Company (4 of 4)
• Figure 4-5: Growth Factor Products by Company
• Figure 4-6: Cellular Allograft Products by Company
• Figure 4-7: Cell Therapy Products by Company
• Figure 4-8: Hyaluronic Acid Viscosupplementation by Products by Company
• Figure 4-9: Cartilage Repair Products by Company
• Figure 4-10: Class 2 Device Recall GRAFTON DBM (Gel, Flex, Putty, Matrix, Crunch)
• Figure 4-11: Class 2 Device Recall GRAFTON PLUS DBM Paste
• Figure 4-12: Class 2 Device Recall Magnifuse Bone Graft
• Figure 4-13: Class 2 Device Recall Grafton DBF Inject
• Figure 4-14: Class 2 Device Recall OsteoSelect Demineralized Bone Matrix (DBM) Putty
• Figure 4-15: Class 2 Device Recall PROSTIM 10cc INJECTABLE
• Figure 4-16: Class 2 Device Recall Opteform Allograft Disc
• Figure 4-17: Class 2 Device Recall Bioactive Bone Graft Putty
• Figure 4-18: Class 3 Device Recall iFACTOR Peptide Enhanced Bone Graft Putty
• Figure 4-19: ACDF Using Structural Allograft vs. Tritanium C
• Figure 4-20: Clinical Study of Bone Graft Substitutes in Orthopaedic and Spinal Applications
• Figure 4-21: OSTEOAMP Lumbar Fusion Intra-Patient Controlled Study
• Figure 4-22: Rate of Bony Fusion Using NanoBone(R) Synthetic Bone Graft Versus Local Autologous Bone Graft. (BONE)
• Figure 4-23: Demineralized Bone Matrix Rotator Cuff Study
• Figure 4-24: Clinical Outcomes Associated with the Use of ViviGen(R) for the Treatment of Lumbar Degenerative Disc Disease
• Figure 4-25: The Effect of Bone-void Filler on Anterior Knee Pain Following ACL Reconstruction
• Figure 4-26: Long-term Safety and Effectiveness of AUGMENT(R) Injectable Bone Graft Compared to Autologous Bone Graft
• Figure 4-27: Transforaminal Lumbar Interbody Fusion (TLIF)
• Figure 4-28: A Post Market Surveillance on INFUSE Bone Graft
• Figure 4-29: Long-term Safety and Effectiveness of AUGMENT(R) Injectable Bone Graft Compared to Autologous Bone Graft
• Figure 4-30: Evaluation of the Effectiveness of AMPLEX(R) Compared to Autogenous Bone Grafts
• Figure 4-31: Safety, Efficacy, & Use of ViviGen Cellular Bone Matrix Allograft in Orthopaedic Fracture Care
• Figure 4-32: MagnetOs Putty Compared to Trinity Evolution in Patients Undergoing up to Four-level Instrumented Posterolateral Fusion
• Figure 4-33: Clinical Outcomes Associated with the Use of ViviGen(R) for the Treatment of Lumbar Degenerative Disc Disease (ViviGen)
• Figure 4-34: Trinity Elite in Lumbar Fusion
• Figure 4-35: An ACDF Multi-Center Study Using ViviGen Cellular Bone Matrix
• Figure 4-36: ViviGen Cellular Bone Matrix for Hindfoot or Ankle Arthrodesis (ViviGen)
• Figure 4-37: Effect of PRP, PPP, & BMAC on Functional Outcomes Following Hip Arthroscopy for Acetabular Labral Pathologies
• Figure 4-38: Bone Marrow Aspirate Concentrate (BMAC) vs Corticosteroid Injection
• Figure 4-39: BMAC & Allograft vs BMP-2
• Figure 4-40: Bone Marrow Aspirate Concentrate (BMAC)Treatment for Knee Osteoarthritis (BMAC)
• Figure 4-41: Platelet Rich Plasma in Knee Osteoarthritis
• Figure 4-42: Platelet-Rich Plasma (PRP) for Treatment of Symptomatic Lumbar Facet Syndrome of the Spine
• Figure 4-43: A Prospective Study of Clinical Outcomes Following a Single Intradiscal Injection of Bone Marrow Aspirate Concentrate (BMAC) for Single Level Discogenic Low Back Pain
• Figure 4-44: ArtiAid(R) for Knee Osteoarthritis: A Post-market Study
• Figure 4-45: The Effectiveness of Different Doses of Hyaluronic Acid Injections in Knee Osteoarthritis
• Figure 4-46: Euflexxa for the Treatment of Osteoarthritis
• Figure 4-47: MONOVISC for Ankle Joint Pain Relief
• Figure 4-48: MONOVISC for Shoulder Joint Pain Relief
• Figure 4-49: MONOVISC for Hip Joint Pain Relief
• Figure 4-50: Comparison of Hyaluronic Acid and Platelet-Rich Plasma Injections
• Figure 4-51: Prospective Evaluation of ProChondrix CR for Repair of Articular Cartilage Defects on Femoral Condyle and Patella
• Figure 4-52: Osteochondral Allograft in the Surgical Treatment of Basal Joint Arthritis
• Figure 4-53: Phase 2 Clinical Trial of CartiLife(R) in the United States
• Figure 4-54: A Study to Evaluate the Efficacy of BioCartilage(R) Micronized Cartilage Matrix in Microfracture Treatment of Osteochondral Defects
• Figure 5-1: Orthopedic Biomaterials Market by Segment, U.S., 2020 - 2030 (US$M)
• Figure 5-2: Leading Competitors, Orthopedic Biomaterials Market, U.S., 2023 (1 of 2)
• Figure 5-3: Leading Competitors, Orthopedic Biomaterials Market, U.S., 2023 (2 of 2)
• Figure 5-4: SWOT Analysis, Arthrex
• Figure 5-5: SWOT Analysis, Biocomposites
• Figure 5-6: SWOT Analysis, Bioventus
• Figure 5-7: SWOT Analysis, DePuy Synthes
• Figure 5-8: SWOT Analysis, Ferring Pharmaceuticals
• Figure 5-9: SWOT Analysis, Isto Biologics
• Figure 5-10: SWOT Analysis, Medtronic
• Figure 5-11: SWOT Analysis, MTF
• Figure 5-12: SWOT Analysis, NuVasive
• Figure 5-13: SWOT Analysis, Orthofix
• Figure 5-14: SWOT Analysis, Sanofi
• Figure 5-15: SWOT Analysis, Stryker
• Figure 5-16: SWOT Analysis, Terumo
• Figure 5-17: SWOT Analysis, Vericel
• Figure 5-18: SWOT Analysis, Zimmer Biomet
• Figure 6-1: Procedure Codes Investigated, U.S., 2023
• Figure 6-2: Orthopedic Biomaterials Procedures by Segment, U.S., 2020 - 2030
• Figure 6-3: Orthopedic Bone Grafting Procedures by Material, U.S., 2020 - 2030
• Figure 6-4: Orthopedic Bone Grafting Procedures by Indication, U.S., 2020 - 2030 (1 of 2)
• Figure 6-5: Orthopedic Bone Grafting Procedures by Indication, U.S., 2020 - 2030 (2 of 2)
• Figure 6-6: Average Units Used per Procedure by Indication, U.S., 2020 - 2030
• Figure 6-7: Autograft Procedures by Indication, U.S., 2020 - 2030 (1 of 2)
• Figure 6-8: Autograft Procedures by Indication, U.S., 2020 - 2030 (2 of 2)
• Figure 6-9: Allograft Procedures by Indication, U.S., 2020 - 2030 (1 of 2)
• Figure 6-10: Allograft Procedures by Indication, U.S., 2020 - 2030 (2 of 2)
• Figure 6-11: Xenograft Procedures by Indication, U.S., 2020 - 2030 (1 of 2)
• Figure 6-12: Xenograft Procedures by Indication, U.S., 2020 - 2030 (2 of 2)
• Figure 6-13: DBM Procedures by Indication, U.S., 2020 - 2030 (1 of 2)
• Figure 6-14: DBM Procedures by Indication, U.S., 2020 - 2030 (2 of 2)
• Figure 6-15: Synthetic Procedures by Indication, U.S., 2020 - 2030 (1 of 2)
• Figure 6-16: Synthetic Procedures by Indication, U.S., 2020 - 2030 (2 of 2)
• Figure 6-17: Allograft Procedures by Patient Type, U.S., 2020-2030
• Figure 6-18: Xenograft Procedures by Patient Type, U.S., 2020-2030
• Figure 6-19: DBM Procedures by Patient Type, U.S., 2020-2030
• Figure 6-20: Synthetic Procedures by Patient Type, U.S., 2020-2030
• Figure 6-21: Orthopedic Bone Grafting Procedures by Care Setting, U.S., 2020-2030
• Figure 6-22: Orthopedic Growth Factor Procedures by Indication, U.S., 2020 - 2030
• Figure 6-23: Orthopedic Growth Factor Procedures by Care Setting, U.S., 2020 - 2030
• Figure 6-24: Cellular Allograft Procedures by Anatomy, U.S., 2020 - 2030
• Figure 6-25: Cellular Allograft Procedures by Patient Type, U.S., 2020 - 2030
• Figure 6-26: Cellular Allograft Procedures by Care Setting, U.S., 2020 - 2030
• Figure 6-27: Orthopedic Cell Therapy Procedures by Material Type, U.S., 2020 - 2030
• Figure 6-28: Platelet-Rich Plasma Procedures by Indication, U.S., 2020 - 2030 (1 of 2)
• Figure 6-29: Platelet-Rich Plasma Procedures by Indication, U.S., 2020 - 2030 (2 of 2)
• Figure 6-30: Bone Marrow Aspirate Concentrate Procedures by Indication, U.S., 2020 - 2030 (1 of 2)
• Figure 6-31: Bone Marrow Aspirate Concentrate Procedures by Indication, U.S., 2020 - 2030 (2 of 2)
• Figure 6-32: Orthopedic Cell Therapy Procedures by Patient Type, U.S., 2020 - 2030
• Figure 6-33: Orthopedic Cell Therapy Procedures by Care Setting, U.S., 2020 - 2030
• Figure 6-34: Hyaluronic Acid Viscosupplementation Procedures by Injection Cycle, U.S., 2020 - 2030 (1 of 2)
• Figure 6-35: Hyaluronic Acid Viscosupplementation Procedures by Injection Cycle, U.S., 2020 - 2030 (2 of 2)
• Figure 6-36: Hyaluronic Acid Viscosupplementation Procedures by Patient Type, U.S., 2020 - 2030
• Figure 6-37: Hyaluronic Acid Viscosupplementation Procedures by Care Setting, U.S., 2020 - 2030
• Figure 6-38: Orthopedic Cartilage Repair Procedures by Type, U.S., 2020 - 2030 (1 of 2)
• Figure 6-39: Orthopedic Cartilage Repair Procedures by Type, U.S., 2020 - 2030 (2 of 2)
• Figure 6-40: Orthopedic Cartilage Repair Procedures by Patient Type, U.S., 2020 - 2030
• Figure 6-41: Orthopedic Cartilage Repair Procedures by Care Setting, U.S., 2020 - 2030
• Figure 7-1: Orthopedic Bone Graft Substitute Units per Procedure by Indication, U.S., 2020 - 2030
• Figure 7-2: Orthopedic Bone Graft Substitute Market by Segment, U.S., 2020 - 2030 (US$M)
• Figure 7-3: Orthopedic Bone Graft Substitute Market by Segment, U.S., 2020 - 2030 (US$M)
• Figure 7-4: Orthopedic Bone Graft Substitute Market, U.S., 2020 - 2030
• Figure 7-5: Allograft Bone Graft Substitute Market, U.S., 2020 - 2030
• Figure 7-6: Xenograft Bone Graft Substitute Market, U.S., 2020 - 2030
• Figure 7-7: Demineralized Bone Matrix Allograft Bone Graft Substitute Market, U.S., 2020 - 2030
• Figure 7-8: Synthetic Bone Graft Substitute Market, U.S., 2020 - 2030
• Figure 7-9: Synthetic Bone Graft Substitute Market by Generation Type, U.S., 2020 - 2030 (US$M)
• Figure 7-10: Generation 1 Synthetic Bone Graft Substitute Market, U.S., 2020 - 2030
• Figure 7-11: Generation 2 Synthetic Bone Graft Substitute Market, U.S., 2020 - 2030
• Figure 7-12: Allograft Bone Graft Substitute Units Sold by Indication, U.S., 2020 - 2030
• Figure 7-13: Spine Allograft Bone Graft Substitute Units Sold, U.S., 2020 - 2030
• Figure 7-14: Spine Allograft Bone Graft Substitute Units Sold by Product Type, U.S., 2020 - 2030
• Figure 7-15: Trauma Allograft Bone Graft Substitute Units Sold, U.S., 2020 - 2030
• Figure 7-16: Large Joint Reconstruction Allograft Bone Graft Substitute Units Sold, U.S., 2020 - 2030
• Figure 7-17: Allograft Bone Graft Substitute Units Sold by Patient Type, U.S., 2020 - 2030
• Figure 7-18: Allograft Bone Graft Substitute Units Sold by Setting Type, U.S., 2020 - 2030
• Figure 7-19: Allograft Bone Graft Substitute Units Sold by Product Type, U.S., 2020 - 2030 (1 of 2)
• Figure 7-20: Allograft Bone Graft Substitute Units Sold by Product Type, U.S., 2020 - 2030 (2 of 2)
• Figure 7-21: Xenograft Bone Graft Substitute Units Sold by Indication, U.S., 2020 - 2030
• Figure 7-22: Spine Xenograft Bone Graft Substitute Units Sold, U.S., 2020 - 2030
• Figure 7-23: Spine Xenograft Bone Graft Substitute Units Sold by Product Type, U.S., 2020 - 2030
• Figure 7-24: Trauma Xenograft Bone Graft Substitute Units Sold, U.S., 2020 - 2030
• Figure 7-25: Large Joint Reconstruction Xenograft Bone Graft Substitute Units Sold, U.S., 2020 - 2030
• Figure 7-26: Xenograft Bone Graft Substitute Units Sold by Patient Type, U.S., 2020 - 2030
• Figure 7-27: Xenograft Bone Graft Substitute Units Sold by Setting Type, U.S., 2020 - 2030
• Figure 7-28: Xenograft Bone Graft Substitute Units Sold by Product Type, U.S., 2020 - 2030
• Figure 7-29: DBM with Carriers Market, U.S., 2020-2030
• Figure 7-30: DBM without Carriers Market, U.S., 2020-2030
• Figure 7-31: Demineralized Bone Matrix Allograft Bone Graft Substitute Units Sold by Indication, U.S., 2020 - 2030
• Figure 7-32: Spine Demineralized Bone Matrix Allograft Bone Graft Substitute Units Sold, U.S., 2020 - 2030
• Figure 7-33: Spine Demineralized Bone Matrix Bone Graft Substitute Units Sold by Product Type, U.S., 2020 - 2030
• Figure 7-34: Trauma Demineralized Bone Matrix Allograft Bone Graft Substitute Units Sold, U.S., 2020 - 2030
• Figure 7-35: Large Joint Reconstruction Demineralized Bone Matrix Allograft Bone Graft Substitute Units Sold, U.S., 2020 - 2030
• Figure 7-36: Demineralized Bone Matrix Allograft Bone Graft Substitute Units Sold by Patient Type, U.S., 2020 - 2030
• Figure 7-37: Demineralized Bone Matrix Allograft Bone Graft Substitute Units Sold by Setting Type, U.S., 2020 - 2030
• Figure 7-38: Demineralized Bone Matrix Bone Graft Substitute Units Sold by Product Type, U.S., 2020 - 2030 (1 of 2)
• Figure 7-39: Demineralized Bone Matrix Bone Graft Substitute Units Sold by Product Type, U.S., 2020 - 2030 (2 of 2)
• Figure 7-40: Synthetic Bone Graft Substitute Units Sold by Indication, U.S., 2020 - 2030
• Figure 7-41: Spine Synthetic Bone Graft Substitute Units Sold, U.S., 2020 - 2030
• Figure 7-42: Spine Synthetic Bone Graft Substitute Units Sold by Product Type, U.S., 2020 - 2030
• Figure 7-43: Trauma Synthetic Bone Graft Substitute Units Sold, U.S., 2020 - 2030
• Figure 7-44: Large Joint Reconstruction Synthetic Bone Graft Substitute Units Sold, U.S., 2020 - 2030
• Figure 7-45: Synthetic Bone Graft Substitute Units Sold by Patient Type, U.S., 2020 - 2030
• Figure 7-46: Synthetic Bone Graft Substitute Units Sold by Setting Type, U.S., 2020 - 2030
• Figure 7-47: Synthetic Bone Graft Substitute Units Sold by Patient Type, U.S., 2020 - 2030
• Figure 7-48: Synthetic Bone Graft Substitute Units Sold by Product Type, U.S., 2020 - 2030 (1 of 2)
• Figure 7-49: Synthetic Bone Graft Substitute Units Sold by Product Type, U.S., 2020 - 2030 (2 of 2)
• Figure 7-50: Leading Competitors, Orthopedic Bone Graft Substitute Market, U.S., 2023
• Figure 8-1: Orthopedic Growth Factor Market by Segment, U.S., 2020 - 2030 (US$M)
• Figure 8-2: Orthopedic Growth Factor Market, U.S., 2020 - 2030
• Figure 8-3: Cervical Disc Degeneration Orthopedic Growth Factor Market, U.S., 2020 - 2030
• Figure 8-4: Tibial Fracture Orthopedic Growth Factor Market, U.S., 2020 - 2030
• Figure 8-5: Spine Orthopedic Growth Factor Market, U.S., 2020 - 2030
• Figure 8-6: Ankle & Hindfoot Fusion Orthopedic Growth Factor Market, U.S., 2020 - 2030
• Figure 8-7: Cervical Disc Degeneration Growth Factor Units Sold by Setting Type, U.S., 2020 - 2030
• Figure 8-8: Tibial Fracture Growth Factor Units Sold by Setting Type, U.S., 2020 - 2030
• Figure 8-9: Spine Growth Factor Units Sold by Setting Type, U.S., 2020 - 2030
• Figure 8-10: Ankle and Hindfoot Fusion Growth Factor Units Sold by Setting Type, U.S., 2020 - 2030
• Figure 8-11: Leading Competitors, Orthopedic Growth Factor Market, U.S., 2023
• Figure 9-1: Orthopedic Cellular Allograft Market by Segment, U.S., 2020 - 2030 (US$M)
• Figure 9-2: Orthopedic Cellular Allograft Market, U.S., 2020 - 2030
• Figure 9-3: Cervical Spine Orthopedic Cellular Allograft Market, U.S., 2020 - 2030
• Figure 9-4: Lumbar Spine Orthopedic Cellular Allograft Market, U.S., 2020 - 2030
• Figure 9-5: Foot and Ankle Cellular Allograft Market, U.S., 2020 - 2030
• Figure 9-6: Trauma Cellular Allograft Market, U.S., 2020 - 2030
• Figure 9-7: Leading Competitors, Orthopedic Cellular Allograft Market, U.S., 2023
• Figure 10-1: Orthopedic Cell Therapy Market by Segment, U.S., 2020 - 2030 (US$M)
• Figure 10-2: Platelet-Rich Plasma Market, U.S., 2020 - 2030
• Figure 10-3: Bone Marrow Aspirate Concentrate Market, U.S., 2020 - 2030
• Figure 10-4: Platelet-Rich Plasma Units Sold by Indication Anatomy, U.S., 2020 - 2030
• Figure 10-5: Bone Marrow Aspirate Concentrate Units Sold by Indication Anatomy, U.S., 2020 - 2030
• Figure 10-6: Leading Competitors, Orthopedic Cell Therapy Market, U.S., 2023
• Figure 11-1: Hyaluronic Acid Viscosupplementation Market by Segment, U.S., 2020 - 2030 (US$M)
• Figure 11-2: Hyaluronic Acid Viscosupplementation Market, U.S., 2020 - 2030
• Figure 11-3: Single-Injection Hyaluronic Acid Viscosupplementation Market, U.S., 2020 - 2030
• Figure 11-4: Two-Injection Hyaluronic Acid Viscosupplementation Market, U.S., 2020 - 2030
• Figure 11-5: Three-Injection Hyaluronic Acid Viscosupplementation Market, U.S., 2020 - 2030
• Figure 11-6: Five-Injection Hyaluronic Acid Viscosupplementation Market, U.S., 2020 - 2030
• Figure 11-7: Leading Competitors, Hyaluronic Acid Viscosupplementation Market, U.S., 2023
• Figure 12-1: Orthopedic Cartilage Repair Market by Segment, U.S., 2020 - 2030 (US$M)
• Figure 12-2: Osteochondral Allograft Market, U.S., 2020 - 2030
• Figure 12-3: Meniscal Allograft Market, U.S., 2020 - 2030
• Figure 12-4: Autologous Chondrocyte Implantation Market, U.S., 2020 - 2030
• Figure 12-5: Particulated Juvenile Allograft Market, U.S., 2020 - 2030
• Figure 12-6: Microfracture Adjunct Market, U.S., 2020 - 2030
• Figure 12-7: Osteochondral Allograft Cartilage Repair Units Sold by Patient Type, U.S., 2020 - 2030
• Figure 12-8: Meniscal Allograft Cartilage Repair Units Sold by Patient Type, U.S., 2020 - 2030
• Figure 12-9: Autologous Chondrocyte Implantation Cartilage Repair Units Sold by Patient Type, U.S., 2020 - 2030
• Figure 12-10: Particulated Juvenile Cartilage Repair Units Sold by Patient Type, U.S., 2020 - 2030
• Figure 12-11: Microfracture Adjunct Cartilage Repair Units Sold by Patient Type, U.S., 2020 - 2030
• Figure 12-12: Leading Competitors, Orthopedic Cartilage Repair Market, U.S., 2023

Product Description: In 2023, the U.S. orthopedic biomaterials market was valued at over $5.0 billion. This market is projected to grow at a compound annual growth rate (CAGR) of 5.3%, reaching over $7.2 billion during the forecast period. The comprehensive report on the U.S. market for orthopedic biomaterials covers various segments, including bone graft substitutes (allografts, demineralized bone matrices (DBMs), xenografts, and synthetic bone grafts). The report also encompasses orthopedic growth factors, cellular allografts, orthopedic cell therapy (bone marrow aspirate concentrate and platelet-rich plasma), hyaluronic acid (HA) viscosupplementation (single-, two-, three-, and five-injection cycles), and orthopedic cartilage repair. The cartilage repair segment includes osteochondral allografts, meniscal allografts, autologous chondrocyte implantation, particulated juvenile allografts, and microfracture adjuncts.

DATA TYPES INCLUDED

Unit Sales, Average Selling Prices, Market Value & Growth Trends

Forecasts Until 2030, and Historical Data to 2020

Market Drivers & Limiters for Each Segment

Competitive Analysis with Market Shares for Each Segment

Recent Mergers & Acquisitions

COVID-19 Impact on the Digital Dentistry market

Disease Overviews and Demographic Information

Company Profiles, Product Portfolios and SWOT for Top Competitors

U.S. Orthopedic Biomaterials Market Insights

The orthopedic biomaterials market is heavily influenced by demographic trends, especially the aging population and the increasing incidence of osteoarthritis (OA) in the spine. The rise in spinal fusion procedures is closely linked to the growing number of OA cases, which correlate with advancing age. Since the first wave of baby boomers began retiring in 2008, the population at risk for degenerative diseases has expanded, increasing the demand for treatments such as bone grafts.

As the elderly population continues to grow and obesity rates remain high, the prevalence of degenerative diseases is expected to rise. This demographic shift underscores a heightened need for orthopedic biomaterials and restorative procedures, driving market growth throughout the forecast period.

U.S. Orthopedic Biomaterials Market Share Insights

In the U.S. orthopedic biomaterials market, three main competitors dominate: Medtronic, DePuy Synthes, and Stryker.

Medtronic maintained its leading position in 2023, particularly excelling in the bone graft substitute segment and the growth factor market with its successful INFUSE(TM) product.

DePuy Synthes held the second-largest market share, a position it has consistently maintained. The company demonstrated significant strength in the bone graft substitute and cellular allograft segments and also distributed the leading hyaluronic acid product. DePuy Synthes offers a demineralized bone matrix (DBM) product processed by the Musculoskeletal Transplant Foundation (MTF) and the DBX(R) product line, which complements its spinal hardware business. The DBX line includes an osteoinductive and osteoconductive bone graft substitute combined with DBM. Additionally, DePuy Synthes distributes Monovisc(R) and Orthovisc(R), single- and three-injection hyaluronic acid products manufactured by Anika Therapeutics.

Stryker secured the third-largest market share, supported by its extensive product portfolio in the bone graft substitute, growth factor, and cellular allograft markets. This position was largely achieved through strategic acquisitions of several previous competitors.

MARKET SEGMENTATION SUMMARY

U.S. Orthopedic Bone Graft Substitute Market - MedCore - Includes:

Material Type: Autograft, Allograft, Xenograft, Demineralized Bone Matrix, Synthetic.

U.S. Orthopedic Growth Factor Market- MedCore - Includes:

Indication Type: Cervical disc Degeneration, Tibial, Spinal, Ankle & Hindfoot.

Care Setting: Hospital, Non-Hospital.

U.S. Orthopedic Cellular Allograft Market- MedCore - Includes:

Anatomy Type: Cervical Spine, Lumbar Spine, Foot & Ankle Allograft, Trauma Allograft.

Patient Type: Pediatric/Neonatal, Adult.

Care Setting: Hospital, Non-Hospital.

U.S. Orthopedic Cell Therapy Market- MedCore - Includes:

Material Type: Platelet-Rich Plasma, Bone Marrow Aspirate Concentrate.

Patient Type: Pediatric/Neonatal, Adult.

U.S. Hyaluronic Acid Viscosupplementation Market - MedCore - Includes:

Injection Cycle Type: Single, Two, Three, Five-Injection.

Patient Type: Pediatric/Neonatal, Adult.

Care Setting: Hospital, Non-Hospital.

U.S. Orthopedic Cartilage Repair Market- MedCore - Includes:

Treatment Type: Microfracture, OATS, Osteochondral Allograft, Meniscal Allograft, Autologous Chondrocyte Implantation, Particulated Juvenile Allograft, Microfracture Adjunct.

Patient Type: Pediatric/Neonatal, Adult.

Care Setting: Hospital, Non-Hospital.

TABLE OF CONTENT

TABLE of CONTENTS

List of Figures

List of Charts

executive summary

U.S. Orthopedic Biomaterials Market Overview

Competitive Analysis

Market Trends

Market Developments

Procedures Included

Procedure Codes Investigated

Markets Included

Key Report Updates

Version History

research methodology

• Step 1: Project Initiation & Team Selection
• Step 2: Prepare Data Systems and Perform Secondary Research
• Step 3: Preparation for Interviews & Questionnaire Design
• Step 4: Performing Primary Research
• Step 5: Research Analysis: Establishing Baseline Estimates
• Step 6: Market Forecast and Analysis
• Step 7: Identify Strategic Opportunities
• Step 8: Final Review and Market Release
• Step 9: Customer Feedback and Market Monitoring

impact of covid-19 on THE U.S. Orthopedic Biomaterials Market

• 2.1 Introduction
• 2.2 Analysis By Market Segment
  • 2.2.1 Worst Case Scenario
  • 2.2.2 Base Case Scenario
  • 2.2.3 Best Case Scenario

Overview

• 3.1 Introduction

Product Assessment

• 4.1 Introduction
• 4.2 Product Portfolios
  • 4.2.1 Bone Graft Substitutes
  • 4.2.2 Growth Factors
    • 4.2.2.1.1 NELL-1 Bone Biologics
    • 4.2.2.1.2 INFUSE(R) by Medtronic
    • 4.2.2.1.3 OsteoAMP(R) by Bioventus Surgical
    • 4.2.2.1.4 OP-1(TM) by Stryker/Olympus Biotech (Delisted)
    • 4.2.2.1.5 The Osteogrow Study
    • 4.2.2.1.6 AUGMENT(R) Bone Graft
    • 4.2.2.1.7 Amplex(R) Osteobiologic Bone Graft Substitute
    • 4.2.2.1.8 i-Factor(TM) Peptide Bone Matrix
  • 4.2.3 Cellular Allografts
  • 4.2.4 Cell Therapy
    • 4.2.4.1 Platelet-Rich Plasma
    • 4.2.4.2 Bone Marrow Aspirate Concentrate
  • 4.2.5 Hyaluronic Acid Viscosupplementation (HAV)
  • 4.2.6 Cartilage Repair
• 4.3 Regulatory Issues and Recalls
  • 4.3.1 Bone Graft Substitute Market FDA Recalls
  • 4.3.2 Growth Factor Market FDA Recalls
• 4.4 Clinical Trials
  • 4.4.1 Bone Graft Substitute Market Clinical Trials
  • 4.4.2 Growth Factor Market Clinical Trials
  • 4.4.3 Cellular Allograft Market Clinical Trials
  • 4.4.4 Cell Therapy Market Clinical Trials
  • 4.4.5 Hyaluronic Acid Viscosupplementation Market
  • 4.4.6 Cartilage Repair Market Clinical Trials

U.S. Orthopedic Biomaterials Market Overview

• 5.1 Introduction
  • 5.1.1 Bone Graft Substitutes
  • 5.1.2 Growth Factors
  • 5.1.3 Cellular Allografts
  • 5.1.4 Cell Therapies
  • 5.1.5 Hyaluronic Acid (HA) Viscosupplementation
  • 5.1.6 Cartilage Repair
• 5.2 Market Overview & Trend Analysis
• 5.3 Drivers and Limiters
  • 5.3.1 Market Drivers
  • 5.3.2 Market Limiters
• 5.4 Competitive Market Share Analysis
• 5.5 Mergers and Acquisitions
• 5.6 Company Profiles
  • 5.6.1 Arthrex
  • 5.6.2 Biocomposites
  • 5.6.3 Bioventus
  • 5.6.4 DePuy Synthes
  • 5.6.5 Ferring Pharmaceuticals
  • 5.6.6 Isto Biologics
  • 5.6.7 Medtronic
  • 5.6.8 MTF
  • 5.6.9 NuVasive
  • 5.6.10 Orthofix
  • 5.6.11 Sanofi
  • 5.6.12 Stryker
  • 5.6.13 Terumo
  • 5.6.14 Vericel
  • 5.6.15 Zimmer Biomet
• 5.7 SWOT Analysis
  • 5.7.1 Arthrex
  • 5.7.2 Biocomposites
  • 5.7.3 Bioventus
  • 5.7.4 DePuy Synthes
  • 5.7.5 Ferring Pharmaceuticals
  • 5.7.6 Isto Biologics
  • 5.7.7 Medtronic
  • 5.7.8 MTF
  • 5.7.9 NuVasive
  • 5.7.10 Orthofix
  • 5.7.11 Sanofi
  • 5.7.12 Stryker
  • 5.7.13 Terumo
  • 5.7.14 Vericel
  • 5.7.15 Zimmer Biomet

Procedure Numbers

• 6.1 Introduction
• 6.2 Procedures
  • 6.2.1 Total Orthopedic Biomaterial Procedures by Segment
  • 6.2.2 Orthopedic Bone Grafting Procedures
    • 6.2.2.1 Orthopedic Bone Grafting Procedures by Material
    • 6.2.2.2 Orthopedic Bone Grafting Procedures by Indication
    • 6.2.2.2.1 Average Units Used per Procedure by Indication
    • 6.2.2.2.2 Autograft Procedures by Indication
    • 6.2.2.2.3 Allograft Procedures by Indication
    • 6.2.2.2.4 Xenograft Procedures by Indication
    • 6.2.2.2.5 DBM Procedures by Indication
    • 6.2.2.2.6 Synthetic Procedures by Indication
    • 6.2.2.3 Orthopedic Bone Grafting Procedures by Patient Type
    • 6.2.2.3.1 Allograft Procedures by Patient Type
    • 6.2.2.3.2 Xenograft Procedures by Patient Type
    • 6.2.2.3.3 DBM Procedures by Patient Type
    • 6.2.2.3.4 Synthetic Procedures by Patient Type
    • 6.2.2.4 Orthopedic Bone Grafting Procedures by Care Setting
  • 6.2.3 Orthopedic Growth Factor Procedures
    • 6.2.3.1 Orthopedic Growth Factor Procedures by Indication
    • 6.2.3.2 Orthopedic Growth Factor Procedures by Care Setting
  • 6.2.4 Orthopedic Cellular Allograft Procedures
    • 6.2.4.1 Cellular Allograft Procedures by Anatomy
    • 6.2.4.2 Cellular Allograft Procedures by Patient Type
    • 6.2.4.1 Cellular Allograft Procedures by Care Setting
  • 6.2.5 Orthopedic Cell Therapy Procedures
    • 6.2.5.1 Orthopedic Cell Therapy Procedures by Material Type
    • 6.2.5.2 Platelet-Rich Plasma Procedures by Indication
    • 6.2.5.3 Bone Marrow Aspirate Concentrate Procedures by Indication
    • 6.2.5.4 Orthopedic Cell Therapy Procedures by Patient Type
    • 6.2.5.1 Orthopedic Cell Therapy Procedures by Care Setting
  • 6.2.6 Hyaluronic Acid Viscosupplementation Procedures
    • 6.2.6.1 Hyaluronic Acid Viscosupplementation Procedures by Injection Cycle
    • 6.2.6.2 Hyaluronic Acid Viscosupplementation Procedures by Patient Type
    • 6.2.6.1 Hyaluronic Acid Viscosupplementation Procedures by Care Setting
  • 6.2.7 Orthopedic Cartilage Repair Procedures
    • 6.2.7.1 Orthopedic Cartilage Repair Procedures by Type
    • 6.2.7.2 Orthopedic Cartilage Repair Procedures by Patient Type
    • 6.2.7.3 Orthopedic Cartilage Repair Procedures by Care Setting

Orthopedic Bone Graft Substitute Market

• 7.1 Introduction
  • 7.1.1 Units per Procedure by Indication
• 7.2 Market Overview
  • 7.2.1 Orthopedic Bone Graft Substitute Market by Material
  • 7.2.2 Orthopedic Bone Graft Substitute Market by Indication
• 7.3 Market Analysis and Forecast
  • 7.3.1 Orthopedic Bone Graft Substitute Market
  • 7.3.2 Allograft Bone Graft Substitute Market
  • 7.3.3 Xenograft Bone Graft Substitute Market
  • 7.3.4 Demineralized Bone Matrix Allograft Bone Graft Substitute Market
  • 7.3.5 Synthetic Bone Graft Substitute Market
    • 7.3.5.1 Synthetic Bone Graft Substitute Market by Generation Type
    • 7.3.5.1.1 Generation 1 Synthetic Bone Graft Substitute Market
    • 7.3.5.1.2 Generation 2 Synthetic Bone Graft Substitute Market
• 7.4 Unit Analysis
  • 7.4.1 Allograft Bone Graft Substitute Unit Analysis
    • 7.4.1.1 Allograft Bone Graft Substitute Units Sold by Indication
    • 7.4.1.2 Allograft Bone Graft Substitute Units Sold by Patient Type
    • 7.4.1.3 Allograft Bone Graft Substitute Units Sold by Setting
    • 7.4.1.4 Allograft Bone Graft Substitute Units Sold by Product Type
  • 7.4.2 Xenograft Bone Graft Substitute Unit Analysis
    • 7.4.2.1 Xenograft Bone Graft Substitute Units Sold by Indication
    • 7.4.2.2 Xenograft Bone Graft Substitute Units Sold by Patient Type
    • 7.4.2.3 Xenograft Bone Graft Substitute Units Sold by Setting
    • 7.4.2.4 Xenograft Bone Graft Substitute Units Sold by Product Type
  • 7.4.3 Demineralized Bone Matrix Allograft Bone Graft Substitute Unit Analysis
    • 7.4.3.1 Demineralized Bone Matrix Allograft Bone Graft Substitute Units Sold Breakout by Carrier Status
    • 7.4.3.1.1 DBM with Carriers Market
    • 7.4.3.1.2 DBM without Carriers Market
    • 7.4.3.2 Demineralized Bone Matrix Allograft Bone Graft Substitute Units Sold by Indication
    • 7.4.3.3 Demineralized Bone Matrix Allograft Bone Graft Substitute Units Sold by Patient Type
    • 7.4.3.4 Demineralized Bone Matrix Allograft Bone Graft Substitute Units Sold by Setting
    • 7.4.3.5 Demineralized Bone Matrix Allograft Bone Graft Substitute Units Sold by Product Type
  • 7.4.4 Synthetic Bone Graft Substitute Unit Analysis
    • 7.4.4.1 Synthetic Bone Graft Substitute Units Sold by Indication
    • 7.4.4.2 Synthetic Bone Graft Substitute Units Sold by Patient Type
    • 7.4.4.3 Synthetic Bone Graft Substitute Units Sold by Setting
    • 7.4.4.4 Synthetic Bone Graft Substitute Units Sold by Product Type
• 7.5 Drivers and Limiters
  • 7.5.1 Allograft Market
    • 7.5.1.1 Market Drivers
    • 7.5.1.2 Market Limiters
  • 7.5.2 Xenograft Market
    • 7.5.2.1 Market Drivers
    • 7.5.2.2 Market Limiters
  • 7.5.3 Demineralized Bone Matrix Bone Graft Substitute Market
    • 7.5.3.1 Market Drivers
    • 7.5.3.2 Market Limiters
  • 7.5.4 Synthetic Bone Graft Substitute Market
    • 7.5.4.1 Market Drivers
    • 7.5.4.2 Market Limiters
• 7.6 Competitive Market Share Analysis

Orthopedic Growth Factor Market

• 8.1 Introduction
  • 8.1.1 BMP-2 (Medtronic)
  • 8.1.2 PDGF-BB (Wright Medical)
  • 8.1.3 BMP-7 (Ember Therapeutics)
  • 8.1.4 P-15 Synthetic Small Peptide (Cerapedics)
• 8.2 Market Overview
• 8.3 Market Analysis and Forecast
  • 8.3.1 Orthopedic Growth Factor Market
  • 8.3.2 Cervical Disc Degeneration Orthopedic Growth Factor Market
  • 8.3.3 Tibial Fracture Orthopedic Growth Factor Market
  • 8.3.4 Spine Orthopedic Growth Factor Market
  • 8.3.5 Ankle and Hindfoot Fusion Orthopedic Growth Factor Market
• 8.4 Unit Analysis
  • 8.4.1 Cervical Disc Degeneration Growth Factor Units Sold by Setting
  • 8.4.2 Tibial Fracture Growth Factor Units Sold by Setting
  • 8.4.3 Spine Growth Factor Units Sold by Setting
  • 8.4.4 Ankle and Hindfoot Fusion Growth Factor Units Sold by Setting
• 8.5 Drivers and Limiters
  • 8.5.1 Market Drivers
  • 8.5.2 Market Limiters
• 8.6 Competitive Market Share Analysis

orthopedic Cellular Allograft Market

• 9.1 Introduction
  • 9.1.1 Lineage
    • 9.1.1.1 Human Embryonic Stem Cells (hESC)
    • 9.1.1.2 Mesenchymal Stem Cells (MSC)
  • 9.1.2 Other Therapeutic Applications
• 9.2 Market Overview
• 9.3 Market Analysis and Forecast
  • 9.3.1 Orthopedic Cellular Allograft Market
  • 9.3.2 Cervical Spine Orthopedic Cellular Allograft Market
  • 9.3.3 Lumbar Spine Orthopedic Cellular Allograft Market
  • 9.3.4 Foot and Ankle Cellular Allograft Market
  • 9.3.5 Trauma Cellular Allograft Market
• 9.4 Drivers and Limiters
  • 9.4.1 Market Drivers
  • 9.4.2 Market Limiters
• 9.5 Competitive Market Share Analysis

Orthopedic Cell Therapy Market

• 10.1 Introduction
• 10.2 Market Overview
• 10.3 Market Analysis and Forecast
  • 10.3.1 Platelet-Rich Plasma Market
  • 10.3.2 Bone Marrow Aspirate Concentrate Market
• 10.4 Unit Analysis
  • 10.4.1 Platelet-Rich Plasma Units Sold by Indication Anatomy
  • 10.4.2 Bone Marrow Aspirate Concentrate Units Sold by Indication Anatomy
• 10.5 Drivers and Limiters
  • 10.5.1 Market Drivers
  • 10.5.2 Market Limiters
• 10.6 Competitive Market Share Analysis

Hyaluronic Acid Viscosupplementation Market

• 11.1 Introduction
  • 11.1.1 Benefits of Viscosupplementation
  • 11.1.2 Synovial Fluid
  • 11.1.3 Product Types
    • 11.1.3.1 Single-Injection Products
    • 11.1.3.2 Two-Injection Cycle Products
    • 11.1.3.3 Three-Injection Cycle Products
    • 11.1.3.4 Three-/Five-Injection Cycle Products
  • 11.1.4 Reimbursement
• 11.2 Market Overview
• 11.3 Market Analysis and Forecast
  • 11.3.1 Hyaluronic Acid Viscosupplementation Market
  • 11.3.2 Single-Injection Hyaluronic Acid Viscosupplementation Market
  • 11.3.3 Two-Injection Hyaluronic Acid Viscosupplementation Market
  • 11.3.4 Three-Injection Hyaluronic Acid Viscosupplementation Market
  • 11.3.5 Five-Injection Hyaluronic Acid Viscosupplementation Market
• 11.4 Drivers and Limiters
  • 11.4.1 Market Drivers
  • 11.4.2 Market Limiters
• 11.5 Competitive Market Share Analysis

Orthopedic Cartilage Repair Market

• 12.1 Introduction
  • 12.1.1 Anatomy
  • 12.1.2 Methods for Cartilage Repair
    • 12.1.2.1 Microfracture
    • 12.1.2.2 Microfracture Adjunct
    • 12.1.2.3 Osteoarticular Autograft Transfer System
    • 12.1.2.4 Particulated Juvenile Allograft
    • 12.1.2.5 Osteochondral Allograft Transfer
    • 12.1.2.6 Autologous Chondrocyte Implantation
    • 12.1.2.7 Meniscal Allograft Transplantation
• 12.2 Market Overview
• 12.3 Market Analysis and Forecast
  • 12.3.1 Osteochondral Allograft Market
  • 12.3.2 Meniscal Allograft Market
  • 12.3.3 Autologous Chondrocyte Implantation Market
  • 12.3.4 Particulated Juvenile Allograft Market
  • 12.3.5 Microfracture Adjunct Market
• 12.4 Unit Analysis
  • 12.4.1 Osteochondral Allograft Cartilage Repair Units Sold by Patient Type
  • 12.4.2 Meniscal Allograft Cartilage Repair Units Sold by Patient Type
  • 12.4.3 Autologous Chondrocyte Implantation Cartilage Repair Units Sold by Patient Type
  • 12.4.4 Particulated Juvenile Cartilage Repair Units Sold by Patient Type
  • 12.4.5 Microfracture Adjunct Cartilage Repair Units Sold by Patient Type
• 12.5 Drivers and Limiters
  • 12.5.1 Market Drivers
  • 12.5.2 Market Limiters
• 12.6 Competitive Market Share Analysis

Abbreviations